| | Events/Patients (%) | OR | 95% CI | P-value |
|---|
| Sex | | | | < 0.001 |
| Male | 64/565 (11%) | 1.00 | | |
| Female | 86/397 (22%) | 2.17 | 1.52 to 3.09 | |
| Age (years) | | | | 0.462 |
| < 50 | 46/345 (13%) | 1.00 | | |
| 50 to 59 | 42/253 (17%) | 1.31 | 0.83 to 2.07 | |
| 60 to 69 | 39/219 (18%) | 1.42 | 0.89 to 2.27 | |
| ≥ 70 | 23/145 (16%) | 1.24 | 0.72 to 2.15 | |
| ECOG PS | | | | 0.597 |
| 0 | 102/639 (16%) | 1.00 | | |
| 1+ | 47/317 (15%) | 0.90 | 0.61 to 1.32 | |
| Weight (kg) | | | | 0.002 |
| < 66 | 52/233 (22%) | 1.00 | | |
| 66–78 | 38/242 (16%) | 0.64 | 0.40 to 1.02 | |
| 79–90 | 23/247 (9%) | 0.36 | 0.21 to 0.62 | |
| ≥ 91 | 36/233 (15%) | 0.63 | 0.39 to 1.01 | |
| Body mass index (kg/m2) | | | | 0.385 |
| 18.5–25.0 | 64/345 (19%) | 1.00 | | |
| < 18.5 | 3/21 (14%) | 0.74 | 0.21 to 2.59 | |
| 25.1–29.9 | 47/340 (14%) | 0.71 | 0.47 to 1.08 | |
| ≥ 30.0 | 33/226 (15%) | 0.75 | 0.47 to 1.18 | |
| eGFR (ml/min/1.73 m2) | | | | 0.228 |
| > 90 | 71/517 (14%) | 1.00 | | |
| 60–89 | 67/388 (17%) | 1.30 | 0.91 to 1.88 | |
| 45–59 | 8/41 (20%) | 1.46 | 0.64 to 3.30 | |
| 30–44 | 4/13 (31%) | 2.81 | 0.84 to 9.38 | |
| Bilirubin | | | | 0.225 |
| ≤ ULN | 146/913 (16%) | 1.00 | | |
| > ULN | 3/36 (8%) | 0.48 | 0.14 to 1.58 | |
| AST | | | | 0.901 |
| ≤ ULN | 132/843 (16%) | 1.00 | | |
| > ULN | 16/103 (16%) | 0.96 | 0.55 to 1.70 | |
| ALT | | | | 0.108 |
| ≤ ULN | 138/843 (16%) | 1.00 | | |
| > ULN | 11/106 (10%) | 0.58 | 0.30 to 1.12 | |
| History of atopy | | | | 0.279 |
| No | 125/767 (16%) | 1.00 | | |
| Yes | 22/176 (13%) | 0.77 | 0.48 to 1.24 | |
- ALT alanine aminotransferase, AST aspartate aminotransferase, CI confidence interval, ECOG PS Eastern Cooperative Oncology Group performance status, eGFR Estimated glomerular filtration rate, OR odds ratio, ULN upper limit of normal
